NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Stock Has Consensus Price Target of $34.50 According to Analysts

Key Points

• NRx Pharmaceuticals has a “Moderate Buy” consensus rating from eight analysts, with six buy ratings and two sell ratings. The average 12-month price target is $34.50.
• NRXP opened at $2.69 and has traded between $1.62 and $5.05 over the past year. The company recently reported a quarterly loss of $0.44 per share, missing the $0.11 consensus estimate, while revenue of $1.10 million also fell short of expectations.
• NRx is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders; its lead candidate, NRX-101, targets bipolar depression with acute suicidal ideation.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) has received an average rating of "Moderate Buy" from the eight research firms that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $34.50.

Several research firms have issued reports on NRXP. HC Wainwright reaffirmed a "buy" rating on shares of NRx Pharmaceuticals in a research note on Tuesday, August 25th. Wolfe Research began coverage on shares of NRx Pharmaceuticals in a research report on Thursday, October 15th. They issued an "outperform" rating for the company. BTIG Research reissued a "buy" rating and set a $10.00 price objective on shares of NRx Pharmaceuticals in a research note on Monday, September 14th. Weiss Ratings restated a "sell (d-)" rating on shares of NRx Pharmaceuticals in a research report on Wednesday, August 5th. Finally, Wall Street Zen lowered shares of NRx Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th.

NRx Pharmaceuticals Price Performance

NASDAQ NRXP opened at $2.69 on Thursday. NRx Pharmaceuticals has a fifty-two week low of $1.62 and a fifty-two week high of $5.05. The stock has a market cap of $116.47 million, a price-to-earnings ratio of -4.89 and a beta of 2.07. The business has a fifty day moving average of $3.10 and a 200-day moving average of $2.96.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.33). The firm had revenue of $1.10 million during the quarter, compared to analyst estimates of $1.33 million. As a group, analysts anticipate that NRx Pharmaceuticals will post -1.14 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Squarepoint Ops LLC acquired a new stake in shares of NRx Pharmaceuticals during the second quarter worth $54,000. Ethos Financial Group LLC grew its position in shares of NRx Pharmaceuticals by 33.6% in the first quarter. Ethos Financial Group LLC now owns 15,900 shares of the company's stock valued at $34,000 after purchasing an additional 4,000 shares during the period. SBI Securities Co. Ltd. lifted its position in NRx Pharmaceuticals by 292.1% during the third quarter. SBI Securities Co. Ltd. now owns 20,001 shares of the company's stock worth $58,000 after buying an additional 14,900 shares during the period. Prime Capital Investment Advisors LLC acquired a new stake in NRx Pharmaceuticals in the 3rd quarter worth about $364,000. Finally, AdvisorShares Investments LLC boosted its stake in NRx Pharmaceuticals by 28.2% in the 1st quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company's stock worth $896,000 after buying an additional 92,463 shares during the last quarter. Hedge funds and other institutional investors own 4.27% of the company's stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly severe depression and suicidal ideation. The company's research programs are designed to address conditions in which existing therapies may have limited effectiveness or delayed onset.

NRx's lead investigational product is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for bipolar depression with acute suicidal ideation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.